Simultaneous liver–kidney transplantation

Simultaneous liver–kidney transplantation is the definitive transplant strategy considered when active HCV infection has produced established or decompensated cirrhosis in a patient who also requires renal replacement. It is not an automatic consequence of HCV positivity: the decision follows virologic confirmation, assessment of liver injury, and continuing surveillance of candidates whose disease may worsen while they wait for a kidney.

Indication in Advanced Liver Disease

HCV infection is common among kidney transplant candidates, and liver injury can be clinically silent. Studies cited in the transplant evaluation literature found advanced fibrosis or cirrhosis in roughly 10–25% of candidates with HCV infection, including patients whose liver disease remained well compensated and would not otherwise have been suspected. For this reason, candidates with active infection require a thorough hepatic workup, with liver biopsy retained as the gold standard when the extent of fibrosis must be established. Noninvasive tests, including biochemical scores and FibroScan-based elastometry, can reduce the need for biopsy in some settings, but they do not yet provide equivalent reliability for transplant selection.

The decisive boundary is the presence of established or decompensated cirrhosis. Such patients should be referred to the liver transplant team for consideration of simultaneous liver–kidney transplantation rather than being accepted automatically for kidney transplantation alone. The same pathway becomes relevant when a candidate initially considered suitable for a kidney alone develops progressive fibrosis or cirrhosis during the waiting period.

Assessing Kidney Alone Versus Combined Transplantation

Kidney transplantation in a cirrhotic patient carries additional hazards: limited hepatic reserve and poor nutritional status increase perioperative morbidity and mortality, while susceptibility to infectious and metabolic complications may rise and long-term survival may be inferior. In one retrospective analysis of 772 patients with cirrhosis undergoing major surgery, thirty-day mortality was 5.7% among those with the least severe cirrhosis by MELD score, although the usefulness of MELD in kidney transplant recipients is uncertain because serum creatinine is part of the score and only a small proportion of the study population had viral hepatitis.

A consensus conference co-sponsored by the American Society of Transplantation, the American Society of Transplant Surgeons, the American Society of Nephrology, and the United Network for Organ Sharing proposed portal hypertension as a central discriminator in well-compensated cirrhosis. Its specific recommendation was that patients with a wedge hepatic vein pressure below 10 mm Hg could be listed for kidney transplantation alone, although that threshold remained to be validated in practice. Additional criteria used in some programs included the absence of varices on endoscopy and a platelet count above 120 × 10^3/µl. These measures do not erase the underlying risk; they define a narrower group whose hepatic circulation and reserve may still permit a kidney-only operation.

The evidence remains limited for patients with biopsy-proven cirrhosis. In one single-center series, only 26% of the few patients with pretransplant cirrhosis were alive ten years after transplantation. That result reinforces the general agreement that established or decompensated cirrhosis warrants liver-team review for a combined procedure, while also showing why kidney-alone transplantation cannot be chosen from HCV status or creatinine alone.

Waiting-List Surveillance and Escalation

The need for simultaneous liver–kidney transplantation can emerge during a prolonged wait. In some areas of the United States, deceased-donor kidney waiting times approach five to seven years, making a one-time prelisting assessment inadequate. Candidates with active HCV infection require regular evaluation to determine whether liver disease has progressed beyond the conditions under which kidney transplantation alone was acceptable.

Patients who remain viremic should undergo periodic assessment of hepatic disease. Among 13 patients who had repeat liver biopsy while still on the waiting list, eight, or 62%, showed interval worsening of liver histology. By contrast, only seven of 31, or 23%, showed worsening on follow-up biopsies obtained after transplantation. Other studies likewise documented progression of HCV-related liver disease in wait-listed dialysis patients. The contrast makes surveillance an active clinical intervention rather than administrative maintenance: the waiting list itself can become a period in which the transplant plan must be revised.

The KDIGO Workgroup opinion was that candidates with stage 1 or 2 fibrosis on pretransplant biopsy should undergo repeat biopsy every five years, whereas those with stage 3 fibrosis should be reassessed after three years. Once liver disease has progressed to early or established cirrhosis, the candidate should be removed from the kidney-only list and referred to the liver team for consideration of simultaneous liver–kidney transplantation.

HCV Management Before and After Transplantation

The combined-transplant decision is linked to the timing of antiviral treatment. Active chronic HCV infection is established by the coexistence of anti-HCV antibodies and HCV RNA; antibody positivity alone does not distinguish resolved infection from ongoing infection. Once active infection is confirmed, clinicians evaluate both hepatic injury and extrahepatic disease, including cryoglobulinemia-associated vasculitis and immune complex-mediated renal lesions. HCV is the major cause of mixed cryoglobulinemia, and associated kidney disease may present with proteinuria, hematuria, reduced eGFR, nephritic syndrome, or nephrotic syndrome.

The preferred opportunity for HCV eradication is generally before kidney transplantation. Interferon use after kidney transplantation has been associated with an increased risk of allograft rejection, so attempts to clear HCV should be focused on the pretransplant period whenever possible. Sustained virological response before transplantation appears durable in most patients after immunosuppression is introduced, although evidence is limited regarding whether it slows later liver injury. Pretransplant viral clearance may also reduce the risk of posttransplant diabetes and immune complex-mediated glomerular disease, but these benefits were described as supported mainly by limited or anecdotal evidence rather than definitive proof.

Antiviral treatment is not feasible or acceptable for every candidate. Interferon-based therapy can be prolonged, toxic, expensive, and ineffective in a substantial minority; patients may refuse it, withdraw from it, or need to be removed from the waiting list during treatment. Consequently, some HCV RNA-positive patients remain candidates for transplantation without achieving viral clearance. For those whose liver disease has advanced to cirrhosis, however, the transplant question is no longer simply whether a kidney can be offered: it becomes whether renal replacement and hepatic failure should be addressed through a combined procedure.

Broader Allocation Context

The choice of simultaneous liver–kidney transplantation occurs within a wider shortage of transplantable organs. HCV-positive donor kidneys can transmit HCV, and their use remains controversial, but restricting such organs to HCV RNA-positive recipients may shorten waiting time for selected candidates. That option can benefit a patient who is unlikely to receive or respond to antiviral therapy, yet it does not replace hepatic assessment. A recipient may be suitable for an HCV-positive kidney only while liver disease remains compatible with kidney transplantation alone; progression to cirrhosis changes the allocation and surgical pathway.

Thus, simultaneous liver–kidney transplantation functions as both a treatment and a boundary-setting decision. Screening identifies hidden liver injury, biopsy and portal-pressure assessment separate candidates for kidney alone from those requiring combined transplantation, and repeated surveillance detects deterioration during waiting. The procedure is reserved for the point at which the liver has become an independent transplant problem, while the kidney remains an equally urgent one.